Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer

Sponsor
Cancer Trials Ireland
Study ID
NCT00962312
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • capecitabine — DRUG
  • lapatinib ditosylate — DRUG

Study Details

RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib ditosylate together with capecitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving lapatinib ditosylate together with capecitabine works in treating patients with metastatic pancreatic cancer.

Key Dates

Start date
Jan 31, 2009
Status verified
Oct 2012
Primary completion
Dec 31, 2010

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Capecitabine and Lapatinib

Primary Outcome Measure

6-month survival rate [ Time Frame: 6 months ]

Related Studies